<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00789165</url>
  </required_header>
  <id_info>
    <org_study_id>1297368</org_study_id>
    <secondary_id>No grants at this point</secondary_id>
    <nct_id>NCT00789165</nct_id>
  </id_info>
  <brief_title>Empiric Quinidine for Asymptomatic Brugada Syndrome</brief_title>
  <official_title>A Prospective Trial Of Empiric Quinidine Therapy For Asymptomatic Brugada Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Registry of Asymptomatic Brugada Syndrome</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Registry of Asymptomatic Brugada Syndrome</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if quinidine therapy (not guided by the results of
      electrophysiologic studies) will reduce the long-term risk of arrhythmic events in
      asymptomatic Brugada Syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2009</start_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined endpoint of all cause mortality and spontaneous life-threatening arrhythmias.</measure>
    <time_frame>Long term (&gt;5 years)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Arrhythmia</condition>
  <arm_group>
    <arm_group_label>Quinidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with type I Brugada electrocardiogram (either spontaneous or following a drug challenge with sodium channel blocker) who never experienced arrhythmia-related symptoms. Patients will receive quinidine therapy at the discretion of the attending physician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with asymptomatic Brugada syndrome who opted to receive no therapy following the recommendation of their attending physician</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>quinidine</intervention_name>
    <description>quinidine at highest tolerated dose. Expected doses are hydroquinidine 600 - 900 mg daily.</description>
    <arm_group_label>Quinidine</arm_group_label>
    <arm_group_label>no therapy</arm_group_label>
    <other_name>Serecor</other_name>
    <other_name>Quiniduran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>no therapy</intervention_name>
    <description>No therapy; this is not a placebo-controlled trial</description>
    <arm_group_label>no therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with Asymptomatic Brugada syndrome.

               -  &quot;Brugada syndrome&quot; is defined as the presence of a Type-I Brugada
                  electrocardiogram [coved ST-segment elevation â‰¥2 mm (0.2 mV) in V1, V2 or V3]
                  either spontaneously (at rest, in the baseline state or during a febrile episode)
                  or following a standard drug-challenge test (with flecainide, ajmaline,
                  procainamide, or pilsicainide) and recorded either with standard electrode
                  position or with the precordial electrodes placed on the second or third
                  intercostal space. Negative T waves in the precordial leads are not required to
                  define a Type I electrocardiogram.

               -  &quot;Asymptomatic patients&quot; will be defined as patients without a history of cardiac
                  arrest, a history of &quot;arrhythmic syncope&quot; or a history of &quot;suspected arrhythmic
                  syncope.&quot; Arrhythmic syncope&quot; is a syncope occurring during documented
                  ventricular tachyarrhythmias. &quot;Suspected arrhythmic syncope&quot; is syncope without
                  documented arrhythmias believed to be caused by a tachyarrhythmia based on
                  clinical judgment. In other words, patients with typical vagal syncope will be
                  counted as &quot;asymptomatic&quot; and will be accepted to the registry whereas patients
                  with a clinical history suggesting &quot;syncope other than vagal syncope&quot; will not be
                  accepted to this Registry.

               -  Genetic confirmation (identification of a disease-causing mutation) will not be
                  required for establishing the diagnosis of Brugada syndrome but will be recorded
                  when present.

          2. Patients with Questionable Brugada Syndrome who are asymptomatic.

               -  Patients with &quot;Questionable Brugada Syndrome&quot; are defined as patients with type
                  II or III electrocardiogram who have an inconclusive result during a drug
                  challenge with a sodium channel blocker. &quot;Asymptomatic&quot; is defined as above.

               -  Genetic testing will not be required. However, patients with &quot;Questionable
                  Brugada&quot; based on electrocardiographic criteria will be defined as &quot;Patients with
                  Brugada Syndrome&quot; if a disease-causing mutation is identified.

        Exclusion Criteria:

          1. A history of cardiac arrest, &quot;arrhythmic syncope&quot; or &quot;suspected arrhythmic syncope&quot;
             (as defined above).

          2. Evidence of organic heart disease. The evaluation considered mandatory for excluding
             heart disease will consist of electrocardiogram, echocardiogram and exercise stress
             testing. Additional tests will be performed only if clinically indicated.

          3. Evidence of non-cardiac disease likely to affect 5-year survival.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sami Viskin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel Aviv Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sami Viskin, M.D.</last_name>
    <phone>97236973311</phone>
    <email>saviskin@tasmc.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lankenau Institute for Medical Research</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charles Antzelevitch, PhD, FACC, FAHA, FHRS</last_name>
      <phone>(315) 725-1390</phone>
      <email>cantzelevitch@gmaill.com</email>
    </contact>
    <investigator>
      <last_name>Charles Antzelevitch, PhD, FACC, FAHA, FHRS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris Rudic, MD</last_name>
      <email>boris.rudic@umm.de</email>
    </contact>
    <investigator>
      <last_name>Boris Rudic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sami Viskin, M.D.</last_name>
      <phone>972524266859</phone>
      <email>saviskin@tasmc.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Bernard Belhassen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pavia and IRCCS Fondazione Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lia Crotti, MD PhD</last_name>
      <email>l.crotti@smatteo.pv.it</email>
    </contact>
    <investigator>
      <last_name>Lia Crotti, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter J Schwartz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cardiovascular Center</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wataru Shimizu, M.D.</last_name>
      <email>:wshimizu@hsp.ncvc.go.jp</email>
    </contact>
    <investigator>
      <last_name>Wataru Shimizu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arthur AM Wilde, M.D.</last_name>
      <email>a.a.wilde@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>Hanno L. Tan, M.D. PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arthur AM Wilde, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2008</study_first_submitted>
  <study_first_submitted_qc>November 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2008</study_first_posted>
  <last_update_submitted>January 8, 2017</last_update_submitted>
  <last_update_submitted_qc>January 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>International Registry of Asymptomatic Brugada Syndrome</investigator_affiliation>
    <investigator_full_name>Dr. Sami Viskin</investigator_full_name>
    <investigator_title>International RABS director</investigator_title>
  </responsible_party>
  <keyword>Brugada syndrome</keyword>
  <keyword>quinidine</keyword>
  <keyword>Asymptomatic Brugada Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Brugada Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quinidine</mesh_term>
    <mesh_term>Quinidine gluconate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

